Tonix Pharmaceuticals (TNXP) Investor presentation summary

Strategic focus and financial position

• Commercial-stage biotech focused on chronic and complex conditions with large unmet needs.

• $185.5M in cash and cash equivalents as of March 31, 2026, with no debt; expected runway into early Q2 2027.

• Priorities include executing the TONMYA launch and advancing a diversified mid-stage clinical pipeline.

TONMYA for fibromyalgia: launch, differentiation, and market opportunity

• TONMYA is the first FDA-approved fibromyalgia treatment for adults in over 15 years, launched November 2025.

• Addresses a large, dissatisfied patient population; 85% of first-line treatments fail due to efficacy and tolerability issues.

• Unique sublingual, non-opioid formulation designed for long-term use, with rapid absorption and robust efficacy.

• Two pivotal Phase 3 studies showed statistically significant pain reduction and sustained efficacy.

• Net sales reached $5.1M from launch to March 31, 2026, with over 11,000 prescriptions by May 2026.

Commercial execution and patient access

• Targeted HCP strategy focuses on 5% of prescribers who write 70% of fibromyalgia prescriptions.

• 100 sales reps deployed; two commercial coverage agreements secured, covering ~52 million lives.

• TONMYA is covered by Medicare in nearly all states and available under Medicaid for ~75 million lives.

• Robust patient support includes copay assistance, digital pharmacy, and home delivery.